{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:47:15Z","timestamp":1793170035522,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","amjmed.com","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.amjmed.2024.06.030","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:59:08Z","timestamp":1720281548000},"page":"1136-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Association Between SGLT2 Inhibitors and Risk of Dementia and Parkinson's Disease: A Meta-Analysis of 12 Randomized Controlled Trials"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1660","authenticated-orcid":false,"given":"Vikash","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Mashkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishchita","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kripa","family":"Rajak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjmed.2024.06.030_bib0001","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ehf2.13805","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis","volume":"9","author":"Pandey","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"12","key":"10.1016\/j.amjmed.2024.06.030_bib0002","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.06.030_bib0003","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.amjmed.2024.06.030_bib0004","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13300-024-01538-1","article-title":"Risk of dementia in patients with diabetes using sodium-glucose transporter 2 inhibitors (SGLT2i): a systematic review, meta-analysis, and meta-regression","volume":"15","author":"Gunawan","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.amjmed.2024.06.030_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2024.101131","article-title":"Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"73","author":"Youn","year":"2024","journal-title":"Front Neuroendocrinol"},{"issue":"7","key":"10.1016\/j.amjmed.2024.06.030_bib0006","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.amjmed.2024.06.030_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2024.06.030_bib0008","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.amjmed.2024.06.030_bib0009","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2024.06.030_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.06.030_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.amjmed.2024.06.030_bib0012","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.amjmed.2024.06.030_bib0013","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2024.06.030_bib0014","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.amjmed.2024.06.030_bib0015","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2024.06.030_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/db20-32-OR","article-title":"32-OR: the Bexagliflozin Efficacy and Safety Trial (BEST): a randomized, double-blind, placebo-controlled, phase IIII, clinical trial","volume":"69","author":"McMurray","year":"2020","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.amjmed.2024.06.030_bib0017","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0929-6646(09)60402-2","article-title":"Risk factors for dementia","volume":"108","author":"Chen","year":"2009","journal-title":"J Formos Med Assoc"},{"issue":"23","key":"10.1016\/j.amjmed.2024.06.030_bib0018","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324004200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324004200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T09:07:43Z","timestamp":1737623263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324004200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0002934324004200"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.06.030","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between SGLT2 Inhibitors and Risk of Dementia and Parkinson's Disease: A Meta-Analysis of 12 Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}